

Publications 2019

Publications à l'initiative des médecins et scientifiques du Centre Oscar Lambret

Thématique Radiothérapie et Radiophysique (12 articles)

Outcomes of pre-operative brachytherapy followed by hysterectomy for early cervical cancer. **Bataille B, Escande A, Le Tinier F, Parent A, Bogart E, Collinet P, Bresson L, Narducci F, Leblanc E, Lemaire AS, Taieb S, Lartigau E, Mirabel X, Cordoba A.** *Int J Gynecol Cancer.* 2019 Dec 22.

Scouarnec C, Pasquier D, Luu J, le Tinier F, Lebellec L, Rault E, Lartigau E, Mirabel X. Usefulness of Stereotactic Body Radiation Therapy for Treatment of Adrenal Gland Metastases. *Front Oncol* 2019 ; 9 : 732

Brassart C, Basson L, Olivier J, Latorzeff I, De Crevoisier R, Lartigau E, Pasquier D. [The radiation oncologist, one of the actors in the patient's path after cancer. Follow up after prostate cancer]. *Cancer Radiother* 2019 ; 23 : 565-571

Pasquier D, Lacornerie T, Mirabel X, Brassart C, Vanquin L, Lartigau E. [Stereotactic body radiotherapy. How to better protect normal tissues?] *Cancer Radiother* 2019 ; 23 : 630-635

Pasquier D, Le Deley MC, Tresch E, Cormier L, Duterque M, Nenon S, Lartigau E. GETUG-AFU 31: a phase I/II multicentre study evaluating the safety and efficacy of salvage stereotactic radiation in patients with intraprostatic tumour recurrence after external radiation therapy-study protocol. *BMJ Open* 2019 ; 9 : e026666

Pasquier D, Martinage G, Janoray G, Rojas DP, Zerini D, Goupy F, De Crevoisier R, Bogart E, Calais G, Toledano A, Chauveinc L, Scher N, Bondiau PY, Hannoun-Levi JM, Silva M, Meyer E, Nickers P, Lacornerie T, Jereczek-Fossa BA, Lartigau E. Salvage Stereotactic Body Radiation Therapy for Local Prostate Cancer Recurrence After Radiation Therapy: A Retrospective Multicenter Study of the GETUG. *Int J Radiat Oncol Biol Phys* 2019 ; 105 : 727-734

Vanquin L, Boydev C, Korhonen J, Rault E, Crop F, Lacornerie T, Wagner A, Laffarguette J, Pasquier D, Reynaert N. [Radiotherapy treatment planning of prostate cancer using magnetic resonance imaging]. *Cancer Radiother* 2019 ; 23 : 281-289

Martinage G, Geffrelot J, Stefan D, Bogart E, Rault E, Reyns N, Emery E, Makhloufi-Martinage S, Mouttet-Audouard R, Basson L, Mirabel X, Lartigau E, Pasquier D. Efficacy and Tolerance of Post-operative Hypo-Fractionated Stereotactic Radiotherapy in a Large Series of Patients With Brain Metastases. *Front Oncol* 2019 ; 9 : 184

Fessart E, Crop F, Tresch E, Mirabel X, Lartigau E, Pasquier D. [Left-sided breast cancer locoregional radiation therapy with rotational intensity-modulated irradiation and deep inspiration breath hold: Dosimetric comparison]. *Cancer Radiother* 2019 ; 23 : 92-97

Olivier J, Basson L, Puech P, Lacornerie T, Villers A, Wallet J, Lartigau E, Pasquier D. Stereotactic Re-irradiation for Local Recurrence in the Prostatic Bed After Prostatectomy: Preliminary Results. *Front Oncol* 2019 ; 9 : 71

Pasquier D, Le Tinier F, Bennadji R, Jouin A, Horn S, Escande A, Tresch E, Chauvet MP, Mailliez A, Crop F, Mirabel X, Lartigau E. Intensity-modulated radiation therapy with simultaneous integrated boost for locally advanced breast cancer: a prospective study on toxicity and quality of life. *Sci Rep* 2019 ; 9 : 2759

Pasquier D, Darloy F, Dewas S, Gras L, Maillard S, Rhliouch H, Tokarski M, Wagner JP, Degrendel-Courtecuisse AC, Dufour C, Fares M, Gilbeau L, Olszyk O, Castelain B, Lartigau E. Harmonization of practices between radiotherapy centres in the Nord and Pas-de-Calais regions (France): A three-year evaluation. *Cancer Radiother* 2019 ; 23 : 10-16

Thématiques Sénologie (6 articles)

Pasquier D, Darlix A, Louvel G, Fraisse J, Jacot W, Brain E, Petit A, Mouret-Reynier MA, Goncalves A, Dalenc F, Deluche E, Fresnel JS, Augereau P, Ferrero JM, Geffrelet J, Fumet JD, Lecouillard I, Cottu P, Petit T, Uwer L, Jouannaud C, Leheurteur M, Dieras V, Robain M, Mouttet-Audouard R, Bachelot T, Courtinard C. Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort. *Eur J Cancer* 2019 ; 125 : 22-30

Le Rhun E, Wallet J, Mailliez A, Le Deley MC, Rodrigues I, Boulanger T, Lorgis V, Barrière J, Robin YM, Weller M, Bonneterre J. Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer. *Neuro Oncol* 2019

Quemener J, Wallet J, Boulanger L, Hannebicque K, Chauvet MP, Régis C. Decision-making determinants for breast reconstruction in women over 65 years old. *Breast J* 2019 ; 25 : 1235-1240

Hajjaji N, Robin YM, Bonneterre J. Should a Multigene Signature be Used in all Luminal Early Breast Cancers. *Front Oncol* 2019 ; 9 : 454

Ceugnart L, Olivier A, Oudoux A. [Breast cancer: News tools in imaging]. *Presse Med.* 2019 Oct;48(10):1101-1111. doi: 10.1016/j.lpm.2019.10.007. Epub 2019 Oct 29.

Chauvet MP. [New surgery]. *Presse Med.* 2019 Oct;48(10):1123-1130. doi: 10.1016/j.lpm.2019.08.020.

Thématique Sarcome et Tumeurs rares (6 articles)

Cordoba A, Prades J, Basson L, Robin YM, Taïeb S, Narducci F, Hudry D, Bresson L, Chevalier A, Le Tinier F, Mirabel X, Lartigau E, Penel N, Leblanc E. Adjuvant management of operated uterine sarcomas: A single institution experience. *Cancer Radiother* 2019 ; 23 : 401-407

Penel N, Ryckewaert T, Le Deley MC. Emerging Role of Multikinase Inhibitors in Desmoid Tumor Management. Am J Clin Oncol 2019 ; 42 : 958

Blay JY, Bonvalot S, Gouin F, Le Cesne A, **Penel N.** Criteria for reference centers for sarcomas: volume but also long-term multidisciplinary organisation. Ann Oncol 2019 ; 30 : 2008-2009

Penel N, Decoupigny E, Tresch-Bruneel E, Le Cesne A, **Taieb S,** Isambert N. Exceptional Long-lasting Clinical Benefit of Trabectedin in a Patient With Metastatic Undifferentiated Pleomorphic Sarcoma: Postscriptum From the T-Dis Trial. Am J Clin Oncol 2019 ; 42 : 737

Penel N, Robin YM, Blay JY. Personalised management of alveolar soft part sarcoma: a promising phase 2 study. Lancet Oncol 2019 ; 20 : 750-752

Decanter G, Stoeckle E, Honore C, Meeus P, Mattei JC, Dubray-Longeras P, Ferron G, Carrere S, Causeret S, Guilloit JM, Fau M, Rosset P, Machiavello JC, Delhorme JB, Regenet N, Gouin F, Blay JY, Coindre JM, **Penel N,** Bonvalot S. Watch and Wait Approach for Re-excision After Unplanned Yet Macroscopically Complete Excision of Extremity and Superficial Truncal Soft Tissue Sarcoma is Safe and Does Not Affect Metastatic Risk or Amputation Rate. Ann Surg Oncol 2019 ; 26 : 3526-3534

Thématique Cancérologie Générale (2 articles)

Adenis A, Bennouna J, Etienne PL, **Bogart E,** Francois E, Galais MP, Ben Abdelghani M, Michel P, Metges JP, Dahan L, Conroy T, Ghiringhelli F, Drouillard A, **El Hajbi F,** Samalin E, Huret S, **Delaine-Clisant S,** Mariette C, **Penel N,** Piessen G, **Le Deley MC.** Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS). Eur J Cancer 2019 ; 111 : 12-20

Makhloufi S, Turpin A, El Amrani M, André T, Truant S, Bachet JB, Vernerey D, Hebbar M. Fong's Score in the Era of Modern Perioperative Chemotherapy for Metastatic Colorectal Cancer: A Post Hoc Analysis of the GERCOR-MIROX Phase III Trial. Ann Surg Oncol. 2019 Oct 22. doi: 10.1245/s10434-019-07976-7.

Thématique Cancérologie Pédiatrique (2 articles)

Sevrin F, Rocourt N, Leroy X, Coulomb-L'Hermine A, **Sudour-Bonnange H.** A Spontaneously Necrotic Wilms' Tumor Mimicking Renal Abscess: A Tricky Diagnosis not to Miss. J Pediatr Hematol Oncol. 2019 Nov 1. doi: 10.1097/MPH.0000000000001645.

Jouin A, Helfre S, Bolle S, Claude L, Laprie A, **Bogart E,** Vigneron C, Potet H, Ducassou A, Claren A, Riet FG, Castex MP, Faure-Contier C, Fresneau B, **Defachelles AS,** Orbach D. Adapted strategy to tumor response in childhood nasopharyngeal carcinoma: the French experience. Strahlenther Onkol 2019 ; 195 : 504-516

Thématique Cancérologie Gynécologique (3 articles)

Hudry D, Narducci F, Andrade C, Leblanc E. Extra-peritoneal para-aortic lymphadenectomy by robot assisted laparoscopy (EPLRL) in 10 steps. *Gynecol Oncol* 2019 ; 155 : 170-171

Belhadia M, Narducci F, Leblanc E, Borghesi Y, Boukerrou M, Hersant B. [How I do... to use indocyanine green to check the flap viability in vaginal reconstruction]. *Gynecol Obstet Fertil Senol* 2019 ; 47 : 484-486

Pannier D, Cordoba A, Ryckewaert T, Robin YM, Penel N. Hormonal therapies in uterine sarcomas, aggressive angiomyxoma, and desmoid-type fibromatosis. *Crit Rev Oncol Hematol* 2019 ; 143 : 62-66

Thématique Imagerie médicale (2 articles)

Basson L, Jarraya H, Escande A, Cordoba A, Daghistani R, Pasquier D, Lacornerie T, Lartigau E, Mirabel X. Chest Magnetic Resonance Imaging Decreases Inter-observer Variability of Gross Target Volume for Lung Tumors. *Front Oncol* 2019 ; 9 : 690

Ceugnart L, Rocourt N, Ben Haj-Amor M, Bachellet F, Boulanger T, Chaveron C, Pouliquen G, Renaud A, Taieb S. [French program of breast cancer screening: Radiologist viewpoint]. *Bull Cancer* 2019 ; 106 : 684-692

Autres publications

Vanseymortier M, Theyry J, Penel N. [Evolution of the regulatory framework in clinical research]. *Bull Cancer* 2019 ; 106 : 389-394

Reich M, Tessier W, Lemaire J, Penel N. "Impossible" patients in oncology: Two unusual cases. *Palliat Support Care* 2019 ; 17 : 119-121

Le Rhun E, Devos P, Boulanger T, Smits M, Brandsma D, Rudà R, Furtner J, Hempel JM, Postma TJ, Roth P, Snijders TJ, Winkler F, Winklhofer S, Castellano A, Hattingen E, Capellades J, Gorlia T, Van den Bent M, Wen PY, Bendszus M, Weller M; European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group (BTG) Central Nervous System (CNS) Metastases Committee and the EORTC BTG Imaging Committee. The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal. *Neuro Oncol* 2019 ; 21 : 648-658

Reich M, Bondenet X, Rambaud L, Ait-Kaci F, Sedda AL, Silva AD, Villet S, Gamblin V. Refractory psycho-existential distress and continuous deep sedation until death in palliative care: The French perspective. *Palliat Support Care* 2019 ; : 1-9

Publications associant le COL

Sénologie (23 publications)

Saadeh R, Naga N, **Mesdag V**, **Régis C**. Unusual burn injury to a deep inferior epigastric perforator flap reconstructed breast. *Breast J*. 2019 Sep 8. doi: 10.1111/tbj.13559.

Thomassin-Naggara I, Balleyguier C, **Ceugnart L**, Heid P, Lenczner G, Maire A, Sérador B, Verzaux L, Taourel P; Conseil national professionnel de la radiologie et imagerie médicale (G4). Artificial intelligence and breast screening: French Radiology Community position paper. *Diagn Interv Imaging*. 2019 Oct;100(10):553-566. doi: 10.1016/j.diii.2019.08.005.

Baudry AS, **Vanlemmens L**, Anota A, Cortot A, Piessen G, Christophe V. Profiles of caregivers most at risk of having unmet supportive care needs: Recommendations for healthcare professionals in oncology. *Eur J Oncol Nurs*. 2019 Dec;43:101669. doi: 10.1016/j.ejon.2019.09.010.

Gougis P, Carton M, Tchokothe C, Campone M, Dalenc F, **Mailliez A**, Levy C, Jacot W, Debled M, Leheurteur M, Bachelot T, Hennequin A, Perrin C, Gonçalves A, Uwer L, Eymard JC, Petit T, Mouret-Reynier MA, Chamorey E, Simon G, Saghatchian M, Cailliot C, Le Tourneau C. CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database. *Breast*. 2019 Oct 19;49:17-24. doi: 10.1016/j.breast.2019.10.004.

Cutuli B, Lemanski C, De Lafontan B, **Chauvet MP**, De Lara CT, Mege A, Fric D, Richard-Molard M, Mazouni C, Cuvier C, Carre A, Kirova Y. Ductal Carcinoma in Situ: A French National Survey. Analysis of 2125 Patients. *Clin Breast Cancer*. 2019 Aug 22. doi: 10.1016/j.clbc.2019.08.002.

Dumas A, Vaz Luis I, Bovagnet T, El Mouhebb M, Di Meglio A, Pinto S, Charles C, Dauchy S, Delalogue S, Arveux P, Coutant C, Cottu P, Lesur A, Lerebours F, Tredan O, **Vanlemmens L**, Levy C, Lemonnier J, Mesleard C, Andre F, Menvielle G. Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO). *J Clin Oncol*. 2019 Dec 13;JCO1901726. doi: 10.1200/JCO.19.01726.

Macpherson IR, Spiliopoulou P, Rafii S, Saggese M, Baird RD, Garcia-Corbacho J, Italiano A, **Bonneterre J**, Campone M, Cresti N, Posner J, Takeda Y, Arimura A, Spicer J. A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. *Breast Cancer Res* 2019 ; 22 : 1.

Bidan N, Bailleul-Dubois J, Duval J, Winter M, Denoulet M, **Hannebicque K**, El-Sayed IY, Ginestier C, Forissier V, Charafe-Jauffret E, Macario M, Matsunaga YT, **Meignan S**, Anquez F, Julien S, Bonnefond A, Derhourhi M, Le Bourhis X, Lagadec C. Transcriptomic Analysis of Breast Cancer Stem Cells and Development of a pALDH1A1:mNeptune Reporter System for Live Tracking. *Proteomics* 2019 ; 19 : e1800454

Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Venat-Bouvet L, Cany L, Catala S, Khayat D, Gambotti L, Pauporté I, Faure-Mercier C, Paget-Bailly S, Henriques J, Grouin JM; PHARE trial investigators. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer

(PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. *Lancet* 2019 ; 393 : 2591-2598

Jacot W, Heudel PE, Fraisse J, Gourgou S, Guiu S, Dalenc F, Pistilli B, Campone M, Levy C, Debled M, Leheurteur M, Chaix M, Lefeuvre C, Goncalves A, Uwer L, Ferrero JM, Eymard JC, Petit T, Mouret-Reynier MA, Courtinard C, Cottu P, Robain M, **Mailliez A**. Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program. *Int J Cancer* 2019 ; 145 : 3359-3369

Roux P, Knight S, Cohen M, Classe JM, Mazouni C, **Chauvet MP**, Reyal F, Colombo PE, Jouve E, Chopin N, Daraï E, Coutant C, Lambaudie E, Houvenaeghel G. Tubular and mucinous breast cancer: results of a cohort of 917 patients. *Tumori* 2019 ; 105 : 55-62

Balleyguier C, Dunant A, **Ceugnart L**, Kandel M, **Chauvet MP**, Chérel P, Mazouni C, Henrot P, Rauch P, Chopier J, Zilberman S, Doutriaux-Dumoulin I, Jaffre I, Jalaguier A, Houvenaeghel G, Guérin N, Callonnec F, Chapellier C, Raoust I, Mathieu MC, Rimareix F, Bonastre J, Garbay JR. Preoperative Breast Magnetic Resonance Imaging in Women With Local Ductal Carcinoma in Situ to Optimize Surgical Outcomes: Results From the Randomized Phase III Trial IRCIS. *J Clin Oncol* 2019 ; 37 : 885-892

de Nonneville A, Jauffret C, Gonçalves A, Classe JM, Cohen M, Reyal F, Mazouni C, **Chauvet MP**, Chopin N, Colombo PE, Jouve E, Daraï E, Rouzier R, Coutant C, Gimbergues P, Azuar AS, de Lara CT, Lambaudie E, Houvenaeghel G. Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit. *Breast Cancer Res Treat* 2019 ; 175 : 379-387

Montemurro F, Ellis P, Anton A, Wuerstlein R, Delalogue S, **Bonneterre J**, Quenel-Tueux N, Linn SC, Irahara N, Donica M, Lindegger N, Barrios CH. Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1. *Eur J Cancer* 2019 ; 109 : 92-102

Houvenaeghel G, Lambaudie E, Classe JM, Mazouni C, Giard S, Cohen M, Faure C, Charitansky H, Rouzier R, Daraï E, **Hudry D**, Azuar P, Villet R, Gimbergues P, Tunon de Lara C, Martino M, Fraisse J, Dravet F, **Chauvet MP**, Boher JM. Lymph node positivity in different early breast carcinoma phenotypes: a predictive model. *BMC Cancer* 2019 ; 19 : 45

Turner NC, Telli ML, Rugo HS, **Mailliez A**, Ettl J, Grischke EM, Mina LA, Balmaña J, Fasching PA, Hurvitz SA, Wardley AM, Chappey C, Hannah AL, Robson ME; ABRAZO Study Group. A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). *Clin Cancer Res* 2019 ; 25 : 2717-2724

Pons-Tostivint E, Kirova Y, Lusque A, Campone M, Geffrelet J, Mazouni C, **Mailliez A**, **Pasquier D**, Mdranges N, Firmin N, Crouzet A, Gonçalves A, Jankowski C, De La Motte Rouge T, Pouget N, de La Lande B, Mouttet-Boizat D, Ferrero JM, Uwer L, Eymard JC, Mouret-Reynier MA, Petit T, Robain M, Filleron T, Cailliot C, Dalenc F. Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched Analysis. *Ann Surg Oncol* 2019 ; 26 : 356-365

Cabel L, Carton M, Cheaib B, Pierga JY, Dalenc F, **Mailliez A**, Levy C, Jacot W, Debled M, Leheurteur M, Desmoulins I, Lefeuvre C, Gonçalves A, Uwer L, Ferrero JM, Eymard JC, Petit T, Mouret-Reynier MA, Perrocheau G, Piot I, Pérol D, Simon G, Lerebours F. Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens. *Breast Cancer Res Treat* 2019 ; 173 : 397-406

Congard A, Christophe V, Duprez C, Baudry AS, Antoine P, Lesur A, Loustalot C, Guillemet C, Leclercq M, Segura C, Carlier D, Lefeuvre-Plesse C, Simon H, Frenel JS, **Vanlemmens L**. The self-reported perceptions of the repercussions of the disease and its treatments on daily life for young women with breast cancer and their partners. *J Psychosoc Oncol* 2019 ; 37 : 50-68

Pistilli B, Mazouni C, Zingarello A, Faron M, Saghatchian M, Grynberg M, Spielmann M, Kerbrat P, Roché H, Lorgis V, Bachelot T, Campone M, Levy C, Gonçalves A, Lesur A, Veyret C, **Vanlemmens L**, Lemonnier J, Delalogue S. Individualized Prediction of Menses Recovery After Chemotherapy for Early-stage Breast Cancer: A Nomogram Developed From UNICANCER PACS04 and PACS05 Trials. *Clin Breast Cancer* 2019 ; 19 : 63-70

Houvenaeghel G, de Nonneville A, Cohen M, Classe JM, Reyat F, Mazouni C, Chopin N, Martinez A, Daraï E, Coutant C, Colombo PE, Gimbergues P, **Chauvet MP**, Azuar AS, Rouzier R, de Lara CT, Muracciole X, Agostini A, Gonçalves A, Lambaudie E. Isolated ipsilateral local recurrence of breast cancer: predictive factors and prognostic impact. *Breast Cancer Res Treat* 2019 ; 173 : 111-122

Classe JM, Loaec C, Gimbergues P, Alran S, de Lara CT, Dupre PF, Rouzier R, Faure C, Paillocher N, **Chauvet MP**, Houvenaeghel G, Gutowski M, De Blay P, Verhaeghe JL, Barranger E, Lefeuvre C, Ngo C, Ferron G, Palpacuer C, Campion L. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. *Breast Cancer Res Treat* 2019 ; 173 : 343-352

Darlix A, Louvel G, Fraisse J, Jacot W, Brain E, Debled M, Mouret-Reynier MA, Gonçalves A, Dalenc F, Delalogue S, Campone M, Augereau P, Ferrero JM, Levy C, Fumet JD, Lecouillard I, Cottu P, Petit T, Uwer L, Jouannaud C, Leheurteur M, Dieras V, Robain M, Chevrot M, **Pasquier D**, Bachelot T. Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. *Br J Cancer* 2019 ; 121 : 991-1000

Oncologie pédiatrique (8 publications)

Régnier E, Laprie A, Ducassou A, Bolle S, Supiot S, Muracciole X, Claude L, Chapet S, **Coche-Dequéant B**, Vigneron C, Leseur J, Bondiau PY, Habrand JL, Bernier V. Re-irradiation of locally recurrent pediatric intracranial ependymoma: Experience of the French society of children's cancer. *Radiother Oncol* 2019 ; 132 : 1-7

Dirksen U, Brennan B, Le Deley MC, Cozic N, van den Berg H, Bhadri V, Brichard B, Claude L, Craft A, Amler S, Gaspar N, Gelderblom H, Goldsby R, Gorlick R, Grier HE, Guinbretiere JM, Hauser P, Hjorth L, Janeway K, Juergens H, Judson I, Krailo M, Kruseova J, Kuehne T, Ladenstein R, **Lervat C**, Lessnick SL, Lewis I, Linassier C, Marec-Berard P, Marina N, Morland B, Pacquement H, Paulussen M, Randall RL, Ranft A, Le Teuff G, Wheatley K, Whelan J, Womer R, Oberlin O, Hawkins DS; Euro-E.W.I.N.G. 99 and Ewing 2008 Investigators. High-Dose Chemotherapy Compared With Standard Chemotherapy and

Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. *J Clin Oncol* 2019 ; 37 : 3192-3202

Varlet P, Le Teuff G, **Le Deley MC**, Giangaspero F, Haberler C, Jacques TS, Figarella-Branger D, Pietsch T, Andreiuolo F, Deroulers C, Jaspan T, Jones C, Grill J. WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial. *Neuro Oncol* 2019 ; :

Delebarre M, Dessein R, Lagrée M, Mazingue F, **Sudour-Bonnange H**, Martinot A, Dubos F. Differential risk of severe infection in febrile neutropenia among children with blood cancer or solid tumor. *J Infect* 2019 ; 79 : 95-100

Courade M, Bertrand A, Guerrini-Rousseau L, Pagnier A, Levy D, **Lervat C**, Cojean N, Ribault A, Dugue S, Thouvenin S, Pigué C, Schmitt C, Marec-Berard P. Low-dose ketamine adjuvant treatment for refractory pain in children, adolescents and young adults with cancer: a pilot study. *BMJ Support Palliat Care* 2019 ; :

Tamborlane WV, Barrientos-Pérez M, Fainberg U, Frimer-Larsen H, Hafez M, Hale PM, Jalaludin MY, Kovarenko M, Libman I, Lynch JL, Rao P, Shehadeh N, Turan S, Weghuber D, Barrett T; Ellipse Trial Investigators. Liraglutide in Children and Adolescents with Type 2 Diabetes. *N Engl J Med* 2019 ; 381 : 637-646

Lavoué V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, Bendifallah S, Bolze PA, Bonnet F, Bourgin C, Chabbert-Buffet N, Collinet P, Courbiere B, De la Motte Rouge T, Devouassoux-Shisheboran M, Falandry C, Ferron G, Fournier L, Gladieff L, Golfier F, Gouy S, Guyon F, Lambaudie E, Rios P, Bailey HD, Poulalhon C, Valteau-Couanet D, Schleiermacher G, Bergeron C, Petit A, **Defachelles AS**, Marion G, Sirvent N, Ducassou S, Munzer C, Orsi L, Lacour B, Clavel J. Parental smoking, maternal alcohol consumption during pregnancy and the risk of neuroblastoma in children. A pooled analysis of the ESCALE and ESTELLE French studies. *Int J Cancer* 2019 ; 145 : 2907-2916

Marec-Berard P, Laurence V, Ocean BV, Ray-Coquard I, Linassier C, Corradini N, Collard O, Chaigneau L, Cupissol D, Kerbrat P, Saada-Bouzid E, Delcambre C, Gouin F, Guillemet C, Jimenez M, **Lervat C**, Gaspar N, **Le Deley MC**, Brugieres L, Piperno-Neumann S. Methotrexate-Etoposide-Ifosfamide Compared with Doxorubicin-Cisplatin-Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18-25 Years. *J Adolesc Young Adult Oncol* 2019

Oncologie générale (13 publications)

Hammel P1, Kindler HL2, Reni M3, Van Cutsem E4, Macarulla T5, Hall MJ6, Park JO7, Hochhauser D8, Arnold D9, Oh DY10, Reinacher-Schick A11, Tortora G12, Algül H13, O'Reilly EM14, McGuinness D15, Cui KY16, Joo S17, Yoo HK15, Patel N16, Golan T18; POLO Investigators. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. *Ann Oncol*. 2019 Dec 1;30(12):1959-1968. doi: 10.1093/annonc/mdz406.

Turpin A, Genin M, Hebbar M, Occelli F, Lanier C, **Vasseur F**, Descarpentries C, **Pannier D**, Ploquin A. Spatial heterogeneity of KRAS mutations in colorectal cancers in northern France. *Cancer Manag Res*. 2019 Sep 13;11:8337-8344. doi: 10.2147/CMAR.S211119.

Sroussi M, Elaidi R, Fléchon A, Lorcet M, Borchiellini D, Tardy MP, Gravis G, Guérin M, Laguerre B, Estrade F, Delva R, Barthélémy P, Lorient Y, Lavaud P, Leuret T, Neuzillet Y, **Penel N**, Houede N, Pouessel D, Rousseau B, Mussat E, Gross-Goupil M, Culine S, Gauthier H, Gobert A, Roupret M, Huillard O, Tartas S, Radulescu C, Allory Y, Oudard S. Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group. Clin Genitourin Cancer 2019

Chung HC, Piha-Paul SA, Lopez-Martin J, Schellens JHM, Kao S, Miller WH Jr, Delord JP, Gao B, Planchard D, Gottfried M, Zer A, Jalal SI, **Penel N**, Mehnert JM, Matos I, Bennouna J, Kim DW, Xu L, Krishnan S, Norwood K, Ott PA. Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. J Thorac Oncol 2019

Schuler M, Cho BC, Sayehli CM, Navarro A, Soo RA, Richly H, Cassier PA, Tai D, **Penel N**, Nogova L, Park SH, Schostak M, Gajate P, Cathomas R, Rajagopalan P, Grevel J, Bender S, Boix O, Nogai H, Ocker M, Ellinghaus P, Joerger M. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol 2019 ; 20 : 1454-1466

Landi B, Blay JY, Bonvalot S, Brasseur M, Coindre JM, Emile JF, Hautefeuille V, Honore C, **Lartigau E**, Mantion G, Pracht M, Le Cesne A, Ducreux M, Bouche O; «Thésaurus National de Cancérologie Digestive (TNCD)» (Fédération Francophone de Cancérologie Digestive (FFCD); Fédération Nationale de Centres de Lutte Contre les Cancers (UNICANCER); Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR); Société Française de Chirurgie Digestive (SFCD); Société Française de Radiothérapie Oncologique (SFRO); Société Française d'Endoscopie Digestive (SFED); Société Nationale Française de Gastroentérologie (SNFGE). Gastrointestinal stromal tumours (GISTs): French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Dig Liver Dis 2019 ; 51 : 1223-1231

Herbst RS, Arkenau HT, Santana-Davila R, Calvo E, Paz-Ares L, Cassier PA, Bendell J, **Penel N**, Krebs MG, Martin-Liberal J, Isambert N, Soriano A, Wermke M, Cultrera J, Gao L, Widau RC, Mi G, Jin J, Ferry D, Fuchs CS, Petrylak DP, Chau I. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Lancet Oncol 2019 ; 20 : 1109-1123

Jannin A, **Penel N**, Ladsous M, Vantghem MC, Do Cao C. Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders. Crit Rev Oncol Hematol 2019 ; 141 : 23-35

El Ali Z, Rottey S, Barthelemy P, Kotecki N, VAN Paemel R, Devrient D, Awada A, Gil T, **Pannier D**, **Ryckewaert T**, Waisse W, Clavier JB, **Penel N**, Vermassen T. Brain Metastasis and Renal Cell Carcinoma: Prognostic Scores Assessment in the Era of Targeted Therapies. Anticancer Res 2019 ; 39 : 2993-3002

Toulmonde M, Blay JY, Bouche O, Mir O, **Penel N**, Isambert N, Duffaud F, Bompas E, Esnaud T, Boidot R, Geneste D, Ghiringhelli F, Lucchesi C, Bellera CA, Le Loarer F, Italiano A. Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study. Clin Cancer Res 2019 ; 25 : 4611-4615

Vandendorpe B, Durot C, **Lebellec L, Le Deley MC, Sylla D, Bimbai AM**, Amroun K, Ramiandrisoa F, **Cordoba A, Mirabel X**, Hoeffel C, **Pasquier D**, Servagi-Vernat S.. Prognostic value of the texture analysis parameters of the initial computed tomographic scan for response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer. *Radiother Oncol* 2019 ; 135 : 153-160

Cousin S, Le Loarer F, Crombé A, Karanian M, Minard-Colin V, **Penel N**. [Epithelioid hemangioendothelioma]. *Bull Cancer* 2019 ; 106 : 73-83

Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, Lordick F, Kim SB, Tajika M, Kim HT, Lockhart AC, Arkenau HT, **El-Hajbi F**, Gupta M, Pfeiffer P, Liu Q, Lunceford J, Kang SP, Bhagia P, Kato K. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study. *JAMA Oncol* 2019 ; 5 : 546-550

Oncologie gynécologique (18 publications)

Vergote I, Magrina JF, Zanagnolo V, Magtibay PM, Butler K, Gil-Moreno A, Feijoo BD, Kimmig R, Canis M, Bourdel N, Ind T, Estape R, Persson J, Lim P, Coronado P, Ponce J, Lambaudie E, Van Gorp T, Maggioni A, **Narducci F**, Van Niewwenhuysen E, Van Trappen P. The LACC Trial and Minimally Invasive Surgery in Cervical Cancer. *J Minim Invasive Gynecol*. 2019 Sep 11. doi: 10.1016/j.jmig.2019.09.767.

Angeles MA, Mallet E, Rouanet P, Cabarrou B, Méeus P, Lambaudie E, Foucher F, **Narducci F**, Loaec C, Gouy S, Guyon F, Marchal F, Gladiéff L, Martínez-Gómez C, Migliorelli F, Martinez A, Ferron G. Comparison of postoperative complications and quality of life between patients undergoing continent versus non-continent urinary diversion after pelvic exenteration for gynecologic malignancies. *Int J Gynecol Cancer*. 2019 Dec 2. doi: 10.1136/ijgc-2019-000863.

Lee CK, Asher R, Friedlander M, Gebiski V, Gonzalez-Martin A, Lortholary A, Lesoin A, Kurzeder C, Largillier R, Hilpert F, Hardy-Bessard AC, Kaminsky MC, Poveda A, Pujade-Lauraine E. Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy. *Eur J Cancer* 2019 ; 117 : 99-106

Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, Waters J, Berek JS, Woie K, Oza AM, Canzler U, Gil-Martin M, **Lesoin A**, Monk BJ, Lund B, Gilbert L, Wenham RM, Benigno B, Arora S, Hazard SJ, Mirza MR. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial. *J Clin Oncol* 2019 ; 37 : 2968-2973

Reboux PA, Azaïs H, Canova CH, Bendifallah S, Ouldamer L, Raimond E, **Hudry D**, Coutant C, Graesslin O, Touboul C, Collinet P, Bricou A, Huchon C, Daraï E, Ballester M, Lévêque J, Lavoué V, Koskas M, Uzan C, Canlorbe G. Impact of vaginal brachytherapy in intermediate and high-intermediate risk endometrial cancer: a multicenter study from the FRANCOGYN group. *J Gynecol Oncol* 2019 ; 30 : e53

Lavoue V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, Bendifallah S, Bolze PA, Bonnet F, Bourgin C, Chabbert-Buffet N, Collinet P, Courbiere B, De la Motte Rouge T, Devouassoux-Shisheboran M, Falandry C, Ferron G, Fournier L, Gladieff L, Golfier F, Gouy S, Guyon F, Lambaudie E, Leary A, Lecuru F, Lefrere-Belda MA, **Leblanc E**, Lemoine A, **Narducci F**, Ouldamer L, Pautier P, Planchamp F, Pouget N, Ray-Coquard I, Rousset-Jablonski C, Senechal-Davin C, Touboul C, Thomassin-Naggara I, Uzan C, You B, Daraï E. Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. Long text of the Joint French Clinical Practice Guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and endorsed by INCa. Part 1: Diagnostic exploration and J Gynecol Obstet Hum Reprod 2019 ; 48 : 369-378

Lavoue V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, Bendifallah S, Bolze PA, Bonnet F, Bourgin C, Chabbert-Buffet N, Collinet P, Courbiere B, De la Motte Rouge T, Devouassoux-Shisheboran M, Falandry C, Ferron G, Fournier L, Gladieff L, Golfier F, Gouy S, Guyon F, Lambaudie E, Leary A, Lecuru F, Lefrere-Belda MA, **Leblanc E**, Lemoine A, Narducci F, Ouldamer L, Pautier P, Planchamp F, Pouget N, Ray-Coquard I, Rousset-Jablonski C, Senechal-Davin C, Touboul C, Thomassin-Naggara I, Uzan C, You B, Daraï E. Management of epithelial cancer of the ovary, fallopian tube, primary peritoneum. Long text of the joint French clinical practice guidelines issued by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY, endorsed by INCa. (Part 2: systemic, intraperitoneal treatment, elderly patients, fertility preservation, follow-up). J Gynecol Obstet Hum Reprod. 2019 Jun;48(6):379-386.

Lavoue V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, Bendifallah S, Bolze PA, Bonnet F, Bourgin C, Chabbert-Buffet N, Collinet P, Courbiere B, De la Motte Rouge T, Devouassoux-Shisheboran M, Falandry C, Ferron G, Fournier L, Gladieff L, Golfier F, Gouy S, Guyon F, Lambaudie E, Leary A, Lecuru F, Lefrere-Belda MA, **Leblanc E**, Lemoine A, Narducci F, Ouldamer L, Pautier P, Planchamp F, Pouget N, Ray-Coquard I, Rousset-Jablonski C, Senechal-Davin C, Touboul C, Thomassin-Naggara I, Uzan C, You B, Daraï E. Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. Short text of the French Clinical Practice Guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and endorsed by INCa. Eur J Obstet Gynecol Reprod Biol 2019 ; 236 : 214-223

Lavoue V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, Bendifallah S, Bolze PA, Bonnet F, Bourgin C, Chabbert-Buffet N, Collinet P, Courbiere B, De la Motte Rouge T, Devouassoux-Shisheboran M, Falandry C, Ferron G, Fournier L, Gladieff L, Golfier F, Gouy S, Guyon F, Lambaudie E, Leary A, Lecuru F, Lefrere-Belda MA, **Leblanc E**, Lemoine A, Narducci F, Ouldamer L, Pautier P, Planchamp F, Pouget N, Ray-Coquard I, Rousset-Jablonski C, Senechal-Davin C, Touboul C, Thomassin-Naggara I, Uzan C, You B, Daraï E. [Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa]. Bull Cancer 2019 ; 106 : 354-370

Racin A, Raimond E, Bendifallah S, Nyangoh Timoh K, Ouldamer L, Canlorbe G, **Hudry N**, Coutant C, Graesslin O, Touboul C, Collinet P, Bricou A, Huchon C, Koskas M, Ballester M, Daraï E, Levêque J, Lavoue V; groupe de recherche FRANCOGYN. Lymphadenectomy in elderly patients with high-intermediate-risk, high-risk or advanced endometrial cancer: Time to move from personalized cancer medicine to personalized patient medicine! Eur J Surg Oncol 2019 ; 45 : 1388-1395

Ferron G, **Narducci F**, Pouget N, Touboul C. [Surgery for advanced stage ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and end Gynecol Obstet Fertil Senol 2019 ; 47 : 197-213

Angeles MA, Baissas P, **Leblanc E**, Lusque A, Ferron G, Ducassou A, Martínez-Gómez C, Querleu D, Martinez A. Magnetic resonance imaging after external beam radiotherapy and concurrent chemotherapy for locally advanced cervical cancer helps to identify patients at risk of recurrence. Int J Gynecol Cancer 2019; 29 : 480-486

Leary A, Lécuru F, Lefrère-Belda MA, **Leblanc E**, Lemoine A, Narducci F, Ouldamer L, Pautier P, Planchamp F, Pouget N, Ray-Coquard I, Rousset-Jablonski C, Sénéchal-Davin C, Touboul C, Thomassin-Naggara I, Uzan C, You B, Daraï E. [Part II drafted from the short text of the French guidelines entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa. (Systemic and intraperitoneal treatment, elderl Gynecol Obstet Fertil Senol 2019 ; 47 : 111-119

Lemoine A, Lambaudie E, Bonnet F, **Leblanc E** ; Alfonsi P. [Perioperative care of epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF a Gynecol Obstet Fertil Senol 2019 ; 47 : 187-196

Lavoué V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, Bendifallah S, Bolze PA, Bonnet F, Bourgin C, Chabbert-Buffet N, Collinet P, Courbiere B, De la Motte Rouge T, Devouassoux-Shisheboran M, Falandry C, Ferron G, Fournier L, Gladiéff L, Golfier F, Gouy S, Guyon F, Lambaudie E, Leary A, Lécuru F, Lefrère-Belda MA, **Leblanc E**, Lemoine A, Narducci F, Ouldamer L, Pautier P, Planchamp F, Pouget N, Ray-Coquard I, Rousset-Jablonski C, Sénéchal-Davin C, Touboul C, Thomassin-Naggara I, Uzan C, You B, Daraï E. [Part I drafted from the short text of the French Guidelines entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa. (Diagnosis management, surgery, perioperative ca Gynecol Obstet Fertil Senol 2019 ; 47 : 100-110

Romeo C, Joly F, Ray-Coquard I, El Kouri C, Mercier-Blas A, Berton-Rigaud D, Kalbacher E, Cojocarasu O, Fabbro M, Cretin J, Zannetti A, Abadie-Lacourtoisie S, Mollon D, Hardy-Bessard AC, Provansal M, Blot E, Delbaldo C, **Lesoin A**, Freyer G, You B. Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial. Gynecol Oncol 2019 ; 152 : 68-75

Joly F, Ahmed-Lecheheb D, Kalbacher E, Heutte N, Clarisse B, Grellard JM, Gernier F, Berton-Rigaud D, Tredan O, Fabbro M, Savoye AM, Kurtz JE, Alexandre J, Follana P, Delecroix V, Dohollou N, Roemer-Becuwe C, De Rauglaudre G, Lortholary A, Prulhiere K, **Lesoin A**, Zannetti A, N'Guyen S, Trager-Maury S, Chauvenet L, Abadie Lacourtoisie S, Gompel A, Lhommé C, Floquet A, Pautier P. Long-term fatigue and quality of life among epithelial ovarian cancer survivors: a GINECO case/control VIVROVAIRE I study. Ann Oncol 2019 ; 30 : 845-852

Falchook G, Coleman RL, Roszak A, Behbakht K, Matulonis U, Ray-Coquard I, Sawrycki P, Duska LR, Tew W, Ghamande S, **Lesoin A**, Schwartz PE, Buscema J, Fabbro M, Lortholary A, Goff B, Kurzrock R,

Martin LP, Gray HJ, Fu S, Sheldon-Waniga E, Lin HM, Venkatakrishnan K, Zhou X, Leonard EJ, Schilder RJ. Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial. *JAMA Oncol* 2019 ; 5 : e183773

Sarcomes et Tumeurs rares (17 publications)

Khoja L, Atenafu EG, Suci S, Leyvraz S, Sato T, Marshall E, Keilholz U, Zimmer L, Patel SP, Piperno-Neumann S, Piulats J, Kivelä TT, Pfoehler C, Bhatia S, Huppert P, Van Iersel LBJ, De Vries IJM, **Penel N**, Vogl T, Cheng T, Fiorentini G, Mouriaux F, Tarhini A, Patel PM, Carvajal R, Joshua AM. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. *Ann Oncol* 2019 ; 30 : 1370-1380

Pautier P, **Penel N**, Ray-Coquard I, Italiano A, Bompas E, Delcambre C, Bay JO, Bertucci F, Delaye J, Chevreau C, Cupissol D, Bozec L, Eymard JC, Saada E, Isambert N, Guillemet C, Rios M, Piperno-Neumann S, Chenuc G, Duffaud F. A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study). *Eur J Cancer* 2019 ; 125 : 31-37

Penel N, Ryckewaert T, Orbach D. [Systemic treatment for management of aggressive fibromatosis in both adult and children: Level of evidence and unsolved questions]. *Bull Cancer* 2019

Neron M, Sajous C, Thezenas S, Piperno-Neumann S, Reyal F, Laé M, Chakiba C, **Penel N, Ryckewaert T**, Honoré C, Bertucci F, Monneur A, Salas S, Duffaud F, Saada-Bouزيد E, Isambert N, Brahmi M, Ray-Coquard I, Blay JY, Firmin N; French Sarcoma Group (GSF-GETO). Impact of Metastasis Surgery and Alkylating-Agent-Based Chemotherapy on Outcomes of Metastatic Malignant Phyllodes Tumors: A Multicenter Retrospective Study. *Ann Surg Oncol* 2019

Le Cesne A, Marec-Berard P, Blay JY, Gaspar N, Bertucci F, **Penel N**, Bompas E, Cousin S, Toulmonde M, Bessede A, Fridman WH, Sautes-Fridman C, Kind M, Le Loarer F, Pulido M, Italiano A. Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. *Eur J Cancer* 2019 ; 119 : 151-157

Stacchiotti S, Ferrari S, Redondo A, Hindi N, Palmerini E, Vaz Salgado MA, Frezza AM, Casali PG, Gutierrez A, Lopez-Pousa A, Grignani G, Italiano A, LeCesne A, Dumont S, Blay JY, **Penel N**, Bernabeu D, de Alava E, Karanian M, Morosi C, Brich S, Dagrada GP, Vallacchi V, Castelli C, Brenca M, Racanelli D, Maestro R, Collini P, Cruz J, Martin-Broto J. Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. *Lancet Oncol* 2019 ; 20 : 1252-1262

Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C, **Penel N**, Bompas E, Saada E, Bertucci F, Lebbe C, Le Cesne A, Soulie P, Piperno-Neumann S, Sweet S, Cecchi F, Hembrough T, Bellera C, Kind M, Crombe A, Lucchesi C, Le Loarer F, Blay JY, Italiano A. Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. *Lancet Oncol* 2019 ; 20 : 1263-1272

Duffaud F, Piperno-Neumann S, **Penel N**, Blay JY. From rare to well-done: importance of rare tumors in cancer therapeutic advances. *Oncotarget* 2019 ; 10 : 3998-3999

Lacourt A, Amadéo B, Gramond C, Marrer E, Plouvier S, Baldi I, Blay JY, Coindre JM, de Pinieux G, Gouin F, Italiano A, Le Cesne A, Le Loarer F, Monnereau A, Pellegrin I, **Penel N**, Ray-Coquard I, Toulmonde M, Ducimetière F, Mathoulin-Pélissier S; Etiosarc study group. ETIOSARC study : environmental aetiology of sarcomas from a French prospective multicentric population-based case-control study-study protocol. *BMJ Open* 2019 ; 9 : e030013

Brard C, Piperno-Neumann S, Delaye J, Brugières L, Hampson LV, Le Teuff G, **Le Deley MC**, Gaspar N. Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma. *BMJ Open* 2019 ; 9 : e025877

Bonvalot S, Gaignard E, Stoeckle E, Meeus P, **Decanter G**, Carrere S, Honore C, Delhorme JB, Fau M, Tzanis D, Causeret S, Gimbergues P, Guillois JM, Meunier B, Le Cesne A, Ducimetiere F, Toulmonde M, Blay JY. Survival Benefit of the Surgical Management of Retroperitoneal Sarcoma in a Reference Center: A Nationwide Study of the French Sarcoma Group from the NetSarc Database. *Ann Surg Oncol* 2019 ; 26 : 2286-2293

Basse C, Italiano A, **Penel N**, Mir O, Chemin C, Toulmonde M, Duffaud F, Le Cesne A, Chevreau C, Maynou C, Anract P, Gouin F, Rios M, Firmin N, Kurtz JE, Kerbrat P, Piperno-Neumann S, Bertucci F, Rosset P, Isambert N, Bompas E, Dubray-Longeras P, Fiorenza F, Le Maignan C, Chaigneau L, Thyss A, Bouché O, Eymard JC, Delcambre Lair C, Adam J, Karanian M, Lebbé C, Dupré A, Meeus P, Brahmi M, Dufresne A, Ducimetière F, Ray-Coquard I, Blay JY. Sarcomas in patients over 90: Natural history and treatment-A nationwide study over 6 years. *Int J Cancer* 2019 ; 145 : 2135-2143

Duffaud F, Mir O, Boudou-Rouquette P, Piperno-Neumann S, **Penel N**, Bompas E, Delcambre C, Kalbacher E, Italiano A, Collard O, Chevreau C, Saada E, Isambert N, Delaye J, Schiffler C, Bouvier C, Vidal V, Chabaud S, Blay JY; French Sarcoma Group. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. *Lancet Oncol* 2019 ; 20 : 120-133

Carrère S, Tetreau R, Honoré C, Tzanis D, Delhorme JB, Fau M, **Decanter G**, Llacer C, Firmin N, Stoeckle E, Meeus P, Ferron G, Cupissol D, Quénet F, Meunier B, Bonvalot S; GSF-GETO. [What is the best management for a spermatic cord sarcoma in 2018?] *Prog Urol* 2019 ; 29 : 12-17

Crombé A, Brisse HJ, Ledoux P, Haddag-Miliani L, Bouhamama A, **Taieb S**, Le Loarer F, Kind M. Alveolar soft-part sarcoma: can MRI help discriminating from other soft-tissue tumors? A study of the French sarcoma group. *Eur Radiol* 2019 ; 29 : 3170-3182

Blay JY, Honoré C, Stoeckle E, Meeus P, **Jafari M**, Gouin F, Anract P, Ferron G, Rochwerger A, Ropars M, Carrere S, Marchal F, Sirveaux F, Di Marco A, Le Nail LR, Guiramand J, Vaz G, Machiavello JC, Marco O, Causeret S, Gimbergues P, Fiorenza F, Chaigneau L, Guillemin F, Guilloit JM, Dujardin F, Spano JP, Ruzic JC, Michot A, Soibinet P, Bompas E, Chevreau C, Duffaud F, Rios M, Perrin C, Firmin N, Bertucci F, Le Pechoux C, Le Loarer F, Collard O, Karanian-Philippe M, Brahmi M, Dufresne A, Dupré A, Ducimetière F, Giraud A, Pérol D, Toulmonde M, Ray-Coquard I, Italiano A, Le Cesne A, **Penel N**, Bonvalot S. Surgery in reference centers improves survival of sarcoma patients: a nationwide study. *Ann Oncol* 2019 ; 30 : 1143-1153

Decanter G, Bonvalot S. ASO Author Reflections: Does a Nonsystematic Regarding Excision Approach After Complete Unplanned Excision of a Soft Tissue Sarcoma Impact Amputation Rate, Metastatic Risk, or Overall Survival? *Ann Surg Oncol*. 2019 Dec;26(Suppl 3):768-769. doi: 10.1245/s10434-019-07919-2.

Radiothérapie et radiophysique (15 publications)

Plouvier SD, Bernillon P, Ligier K, Theis D, Miquel PH, **Pasquier D**, Rivest LP. Completeness of a newly implemented general cancer registry in northern France: Application of a three-source capture-recapture method. *Rev Epidemiol Sante Publique* 2019 ; 67 : 239-245

Bibault JE, Chaix B, Guillemassé A, Cousin S, **Escande A**, Perrin M, Pienkowski A, Delamon G, Nectoux P, Brouard B A Chatbot Versus Physicians to Provide Information for Patients With Breast Cancer: Blind, Randomized Controlled Noninferiority Trial. *J Med Internet Res*. 2019 Nov 27;21(11):e15787.

Krengli M, Cena T, Zilli T, Jereczek-Fossa BA, De Bari B, Villa Freixa S, Kaanders JHAM, Torrente S, **Pasquier D**, Sole CV, Lutsyk M, Dincbas FO, Habboush Y, Fariselli L, Dragan T, Baumert BG, Khanfir K, Ugurluer G, Thariat J. Radiotherapy in the treatment of extracranial hemangiopericytoma/solitary fibrous tumor: Study from the Rare Cancer Network. *Radiother Oncol* 2019 ; 144 : 114-120

de Jong EEC, Guckenberger M, Andratschke N, Dieckmann K, Hoogeman MS, Milder M, Møller DS, Nyeng TB, Tanadini-Lang S, **Lartigau E**, **Lacornerie T**, Senan S, Verbakel W, Verellen D, De Kerf G, Hurkmans C. Variation in current prescription practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer: Recommendations for prescribing and recording according to the ACROP guideline and ICRU report 91. *Radiother Oncol* 2019 ; :

Bayart E, Azria D, Balosso J, Benderitter M, Cohen-Jonathan Moyal E, Delpon G, Deutsch E, Dutreix M, **Lacornerie T**, Romeo PH, Marchesi V, Maingon P. [RadioTransNet, the French network for preclinical research in oncological radiotherapy]. *Cancer Radiother* 2019 ; 23 : 609-616

Bourdais R, Achkar S, Chauffert-Yvart L, **Pasquier D**, Sargos P, Blanchard P, Latorzeff I. [Prophylactic nodal radiotherapy in prostate cancer]. *Cancer Radiother* 2019 ; 23 : 688-695

Baty M, Créhange G, **Pasquier D**, Palard X, Deleuze A, Gnep K, Key S, Beuzit L, Castelli J, de Crevoisier R. Salvage reirradiation for local prostate cancer recurrence after radiation therapy. For who? When? How? *Cancer Radiother* 2019 ; 23 : 541-558

De Bleser E, Jereczek-Fossa BA, **Pasquier D**, Zilli T, Van As N, Siva S, Fodor A, Dirix P, Gomez-Iturriaga A, Trippa F, Detti B, Ingrosso G, Triggiani L, Bruni A, Alongi F, Reynders D, De Meerleer G, Surgo A, **Loukili K**, Miralbell R, Silva P, Chander S, Di Muzio NG, Maranzano E, Francolini G, Lancia A, Tree A, Deantoni CL, Ponti E, Marvaso G, Goetghebeur E, Ost P. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. *Eur Urol* 2019 ; 76 : 732-739

Tensaouti F, Ducassou A, Chaltiel L, Bolle S, Habrand JL, Alapetite C, **Coche-Dequeant B**, Bernier V, Claude L, Carrie C, Padovani L, Muracciole X, Supiot S, Huchet A, Leseur J, Kerr C, Hangard G, Lisbona A, Goudjil F, Ferrand R, Laprie A. Feasibility of Dose Escalation in Patients With Intracranial Pediatric Ependymoma. *Front Oncol* 2019 ; 9 : 531

Vendrely V, Lemanski C, Gnep K, Barbier E, Hajbi FE, Lledo G, Dahan L, Terrebonne E, Manfredi S, **Mirabel X**, Mammar V, Cowen D, Lepage C, Aparicio T; for FFCD investigators/Collaborators Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase I dose-escalation study with panitumumab (FFCD 0904). *Radiother Oncol* 2019 ; 140 : 84-89

Gardin I, Grégoire V, Gibon D, Kirisli H, **Pasquier D**, Thariat J, Vera P. Radiomics: Principles and radiotherapy applications. *Crit Rev Oncol Hematol* 2019 ; 138 : 44-50

Alhamada H, Simon S, Philippon C, Vandekerckhove C, Jourani Y, Pauly N, VanGestel D, **Reynaert N**. 3D Monte Carlo dosimetry of intraoperative electron radiation therapy (IOERT). *Phys Med* 2019 ; 57 : 207-214

Goupy F, Supiot S, **Pasquier D**, Latorzeff I, Schick U, Monpetit E, Martinage G, Hervé C, Le Proust B, Castelli J, de Crevoisier R. Intensity-modulated radiotherapy for prostate cancer with seminal vesicle involvement (T3b): A multicentric retrospective analysis. *PLoS One* 2019 ; 14 : e0210514

Bockel S, **Escande A**, Dumas I, Manea E, Morice P, Gouy S, Deutsch E, Haie-Meder C, Chargari C. Total Reference Air Kerma is Associated with Late Bowel Morbidity in Locally Advanced Cervical Cancer Patients Treated with Image-Guided Adaptive Brachytherapy. *J Clin Med* 2019 ; 8 :

Vaugier L, Palpacuer C, Rio E, Goineau A, **Pasquier D**, Buthaud X, De Laroche G, Beckendorf V, Sargos P, Créhange G, Pommier P, Loos G, Hasbini A, Latorzeff I, Silva M, Denis F, Lagrange JL, Champion L, Supiot S. Early Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07). *Int J Radiat Oncol Biol Phys* 2019 ; 103 : 1061-1067

Autres publications

Bayar MA, Le Teuff G, Koenig F, **Le Deley MC**, Michiels S. Group sequential adaptive designs in series of time-to-event randomised trials in rare diseases: A simulation study. *Stat Methods Med Res* 2019 : 9,6228021986e+014

Broudic-Guibert M, Blay JY, Vazquez L, Evrard A, Karanian M, **Taïeb S**, Hoog-Labouret N, Oukhatar CMA, Boustany-Grenier R, Arnaud A. Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report. *J Med Case Rep* 2019 ; 13 : 245

Jamme P, Descarpentries C, Gervais R, **Dansin E**, Wislez M, Grégoire V, Richard N, Baldacci S, Rabbe N, Kyheng M, Kherrouche Z, Escande F, Copin MC, Cortot AB. Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice. *Clin Lung Cancer* 2019 ; 20 : 297-304.e1

Parsons MT, Tudini E, Li H, Hahnen E, Wappenschmidt B, Feliubadaló L, Aalfs CM, Agata S, Aittomäki K, Alducci E, Alonso-Cerezo MC, Arnold N, Auber B, Austin R, Azzollini J, Balmaña J, Barbieri E, Bartram CR, Blanco A, Blümcke B, Bonache S, Bonanni B, Borg Å, Bortesi B, Brunet J, Bruzzone C, Bucksch K, Cagnoli G, Caldés T, Caliebe A, Caligo MA, Calvello M, Capone GL, Caputo SM, Carnevali I, Carrasco E, Caux-Moncoutier V, Cavalli P, Cini G, Clarke EM, Concolino P, Cops EJ, Cortesi L, Couch FJ, Darder E, de la Hoya M, Dean M, Debatin I, Del Valle J, Delnatte C, Derive N, Diez O, Ditsch N, Domchek SM, Dutrannoy V, Eccles DM, Ehrencrona H, Enders U, Evans DG, Farra C, Faust U, Felbor U, Feroce I, Fine M, Foulkes WD, Galvao HCR, Gambino G, Gehrig A, Gensini F, Gerdes AM, Germani A, Giesecke J, Gismondi V, Gómez C, Gómez Garcia EB, González S, Grau E, Grill S, Gross E, Guerrieri-Gonzaga A, Guillaud-Bataille M, Gutiérrez-Enríquez S, Haaf T, Hackmann K, Hansen TVO, Harris M, Hauke J, Heinrich T, Hellebrand H, Herold KN, Honisch E, Horvath J, Houdayer C, Hübbel V, Iglesias S, Izquierdo A, James PA, Janssen LAM, Jeschke U, Kaulfuß S, Keupp K, Kiechle M, Kölbl A, Krieger S, Kruse TA, Kvist A, Laloo F, Larsen M, Lattimore VL, Lautrup C, Ledig S, Leinert E, Lewis AL, Lim J, Loeffler M, López-Fernández A, Lucci-Cordisco E, Maass N, Manoukian S, Marabelli M, Matricardi L, Meindl A, Michelli RD, Moghadasi S, Moles-Fernández A, Montagna M, Montalban G, Monteiro AN, Montes E, Mori L, Moserle L, Müller CR, Mundhenke C, Naldi N, Nathanson KL, Navarro M, Nevanlinna H, Nichols CB, Niederacher D, Nielsen HR, Ong KR, Pachter N, Palmero EI, Papi L, Pedersen IS, Peissel B, Perez-Segura P, Pfeifer K, Pineda M, Pohl-Rescigno E, Poplawski NK, Porfirio B, Quante AS, Ramser J, Reis RM, **Revillion F**, Rhiem K, Riboli B, Ritter J, Rivera D, Rofes P, Rump A, Salinas M, Sánchez de Abajo AM, Schmidt G, Schoenwiese U, Seggewiß J, Solanes A, Steinemann D, Stiller M, Stoppa-Lyonnet D, Sullivan KJ, Susman R, Sutter C, Tavgigian SV, Teo SH, Teulé A, Thomassen M, Tibiletti MG, Tischkowitz M, Tognazzo S, Toland AE, Tornero E, Törngren T, Torres-Esquius S, Toss A, Trainer AH, Tucker KM, van Asperen CJ, van Mackelenbergh MT, Varesco L, Vargas-Parra G, Varon R, Vega A, Velasco Á, Vesper AS, Viel A, Vreeswijk MPG, Wagner SA, Waha A, Walker LC, Walters RJ, Wang-Gohrke S, Weber BHF, Weichert W, Wieland K, Wiesmüller L, Witzel I, Wöckel A, Woodward ER, Zachariae S, Zampiga V, Zeder-Göß C; KConFab Investigators, Lázaro C, De Nicolo A, Radice P, Engel C, Schmutzler RK, Goldgar DE, Spurdle AB. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. *Hum Mutat* 2019 ; 40 : 1557-1578

Brard C, Hampson LV, Gaspar N, **Le Deley MC**, Le Teuff G. Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study. *BMC Med Res Methodol* 2019 ; 19 : 85

Mathoulin-Pélissier S, **Penel N**. [Cancer screening words]. *Bull Cancer* 2019 ; 106 : 608-614

Jannin A, Espiard S, Benomar K, Do Cao C, Mycinski B, Porte H, D'Herbomez M, **Penel N**, Vantighem MC. Non-islet-cell tumour hypoglycaemia (NICTH): About a series of 6 cases. *Ann Endocrinol (Paris)* 2019 ; 80 : 21-25

Bay JO, André T, Caux C, Evrard S, Gonçalves A, L'Allemain G, Magné N, Orbach D, **Penel N**, Rodrigues M, Thariat J, Thiery-Vuillemin A, Wislez M; Comité de Rédaction du Bulletin du Cancer. [Some important breakthroughs in oncology and hematology in 2018: A selection by the editorial board of Bulletin du Cancer]. *Bull Cancer* 2019 ; 106 : 12-23

Briot K, Paccou J, Beuzeboc P, **Bonneterre J**, Bouvard B, Confavreux CB, Cormier C, Cortet B, Hannoun-Lévi JM, Hennequin C, Javier RM, Lespessailles E, Mayeur D, Mongiat Artus P, **Vieillard MH**,

Debiais F. French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation. *Joint Bone Spine* 2019 ; 86 : 21-28

Novel diagnostic tool for prediction of variant spliceogenicity derived from a set of 395 combined in silico/in vitro studies: an international collaborative effort. Leman R, Gaildrat P, Le Gac G, Ka C, Fichou Y, Audrezet MP, Caux-Moncoutier V, Caputo SM, Boutry-Kryza N, Léone M, Mazoyer S, Bonnet-Dorion F, Sevenet N, Guillaud-Bataille M, Rouleau E, Bressac-de Paillerets B, Wappenschmidt B, Rossing M, Muller D, Bourdon V, Revillon F, Parsons MT, Rousselin A, Davy G, Castelain G, Castéra L, Sokolowska J, Coulet F, Delnatte C, Férec C, Spurdle AB, Martins A, Krieger S, Houdayer C. *Nucleic Acids Res.* 2019 Dec 21. pii: gkz1212. doi: 10.1093/nar/gkz1212.

Figlioli G, Bogliolo M, Catucci I, Caleca L, Lasheras SV, Pujol R, Kiiski JI, Muranen TA, Barnes DR, Dennis J, Michailidou K, Bolla MK, Leslie G, Aalfs CM; ABCTB Investigators, Adank MA, Adlard J, Agata S, Cadoo K, Agnarsson BA, Ahearn T, Aittomäki K, Ambrosone CB, Andrews L, Anton-Culver H, Antonenkova NN, Arndt V, Arnold N, Aronson KJ, Arun BK, Asseryanis E, Auber B, Auvinen P, Azzollini J, Balmaña J, Barkardottir RB, Barrowdale D, Barwell J, Beane Freeman LE, Beauparlant CJ, Beckmann MW, Behrens S, Benitez J, Berger R, Bermisheva M, Blanco AM, Blomqvist C, Bogdanova NV, Bojesen A, Bojesen SE, Bonanni B, Borg A, Brady AF, Brauch H, Brenner H, Brüning T, Burwinkel B, Buys SS, Caldés T, Caliebe A, Caligo MA, Campa D, Campbell IG, Canzian F, Castelao JE, Chang-Claude J, Chanock SJ, Claes KBM, Clarke CL, Collavoli A, Conner TA, Cox DG, Cybulski C, Czene K, Daly MB, de la Hoya M, Devilee P, Diez O, Ding YC, Dite GS, Ditsch N, Domchek SM, Dorfling CM, Dos-Santos-Silva I, Durda K, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Ellberg C, Eriksson M, Evans DG, Fasching PA, Figueroa J, Flyger H, Foulkes WD, Friebel TM, Friedman E, Gabrielson M, Gaddam P, Gago-Dominguez M, Gao C, Gapstur SM, Garber J, García-Closas M, García-Sáenz JA, Gaudet MM, Gayther SA; GEMO Study Collaborators, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, Guénel P, Gutierrez-Barrera AM, Haeberle L, Haiman CA, Håkansson N, Hall P, Hamann U, Harrington PA, Hein A, Heyworth J, Hillemanns P, Hollestelle A, Hopper JL, Hosgood HD 3rd, Howell A, Hu C, Hulick PJ, Hunter DJ, Imyanitov EN; KConFab, Isaacs C, Jakimovska M, Jakubowska A, James P, Janavicius R, Janni W, John EM, Jones ME, Jung A, Kaaks R, Karlan BY, Khusnutdinova E, Kitahara CM, Konstantopoulou I, Koutros S, Kraft P, Lambrechts D, Lazaro C, Le Marchand L, Lester J, Lesueur F, Lilyquist J, Loud JT, Lu KH, Luben RN, Lubinski J, Mannermaa A, Manoochchri M, Manoukian S, Margolin S, Martens JWM, Maurer T, Mavroudis D, Mebirouk N, Meindl A, Menon U, Miller A, Montagna M, Nathanson KL, Neuhausen SL, Newman WG, Nguyen-Dumont T, Nielsen FC, Nielsen S, Nikitina-Zake L, Offit K, Olah E, Olopade OI, Olshan AF, Olson JE, Olsson H, Osorio A, Ottini L, Peissel B, Peixoto A, Peto J, Plaseska-Karanfilska D, Pocza T, Presneau N, Pujana MA, Punie K, Rack B, Rantala J, Rashid MU, Rau-Murthy R, Rennert G, Lejbkowitz F, Rhenius V, Romero A, Rookus MA, Ross EA, Rossing M, Rudaitis V, Ruebner M, Saloustros E, Sanden K, Santamariña M, Scheuner MT, Schmutzler RK, Schneider M, Scott C, Senter L, Shah M, Sharma P, Shu XO, Simard J, Singer CF, Sohn C, Soucy P, Southey MC, Spinelli JJ, Steele L, Stoppa-Lyonnet D, Tapper WJ, Teixeira MR, Terry MB, Thomassen M, Thompson J, Thull DL, Tischkowitz M, Tollenaar RAEM, Torres D, Troester MA, Truong T, Tung N, Untch M, Vachon CM, van Rensburg EJ, van Veen EM, Vega A, Viel A, Wappenschmidt B, Weitzel JN, Wendt C, Wieme G, Wolk A, Yang XR, Zheng W, Ziogas A, Zorn KK, Dunning AM, Lush M, Wang Q, McGuffog L, Parsons MT, Pharoah PDP, Fostira F, Toland AE, Andrulis IL, Ramus SJ, Swerdlow AJ, Greene MH, Chung WK, Milne RL, Chenevix-Trench G, Dörk T, Schmidt MK, Easton DF, Radice P, Hahnen E, Antoniou AC, Couch FJ, Nevanlinna H, Surrallés J, Peterlongo P. *The FANCM:p.Arg658**

truncating variant is associated with risk of triple-negative breast cancer. *NPJ Breast Cancer*. 2019 Nov 1;5:38. doi: 10.1038/s41523-019-0127-5.

Lefèvre JH, Mineur L, Cachanado M, Denost Q, Rouanet P, de Chaisemartin C, Meunier B, **Mehrdad J**, Cotte E, Desrame J, Karoui M, Benoist S, Kirzin S, Berger A, Panis Y, Piessen G, Saudemont A, Prudhomme M, Peschaud F, Dubois A, Loriau J, Tuech JJ, Meurette G, Lupinacci R, Goasguen N, Creavin B, Simon T, Parc Y; The French Research Group of Rectal Cancer Surgery (GRECCAR). Does A Longer Waiting Period After Neoadjuvant Radio-chemotherapy Improve the Oncological Prognosis of Rectal Cancer?: Three Years' Follow-up Results of the Greccar-6 Randomized Multicenter Trial. *Ann Surg*. 2019 Nov;270(5):747-754. doi: 10.1097/SLA.0000000000003530.

Moya-Plana A, Aupérin A, Obongo R, Baglin A, Ferrand FR, Baujat B, Saroul N, Casiraghi O, Vergez S, Herman P, Janot F, Thariat J, Vérillaud B, de Gabory L; REFCOR members. Oncologic outcomes, prognostic factor analysis and therapeutic algorithm evaluation of head and neck mucosal melanomas in France. *Eur J Cancer*. 2019 Dec;123:1-10. doi: 10.1016/j.ejca.2019.09.007.

Bouras AF, Liddo G, Marx-Deseure A, Leroy A, **Decanter G**. Accessible laparoscopic liver resection performed in low volume centers: Is it time for democratization? *J Visc Surg*. 2019 Oct 24. doi: 10.1016/j.jvisc.2019.10.003.

Ogrinc N, Saudemont P, Balog J, **Robin YM**, Gimeno JP, Pascal Q, Tierny D, Takats Z, Salzet M, Fournier I. Water-assisted laser desorption/ionization mass spectrometry for minimally invasive in vivo and real-time surface analysis using SpiderMass. *Nat Protoc*. 2019 Nov;14(11):3162-3182. doi: 10.1038/s41596-019-0217-8.

Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Henderson D, Brown S, Cruickshank C, Burnett S, Duffton A, Griffin C, Hinder V, Morrison K, Naismith O, Hall E, van As N; PACE Trial Investigators. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. *Lancet Oncol*. 2019 Nov;20(11):1531-1543.

Lechien JR, Seminerio I, Descamps G, Mat Q, Mouawad F, Hans S, **Julieron M**, **Dequanter D**, Vanderhaegen T, Journe F, Saussez S. Impact of HPV Infection on the Immune System in Oropharyngeal and Non-Oropharyngeal Squamous Cell Carcinoma: A Systematic Review. *Cells*. 2019 Sep 10;8(9). pii: E1061. doi: 10.3390/cells8091061.

Descourt R, Perol M, Rousseau-Bussac G, Planchard D, Mennequier B, Wislez M, Cortot A, Guisier F, Galland L, Dô P, Schott R, **Dansin E**, Arrondeau J, Auliac JB, Chouaid C. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study). *Lung Cancer*. 2019 Oct;136:109-114. doi: 10.1016/j.lungcan.2019.08.010.

Marti-Flich L, Schlund M, Raoul G, Maes JM, Ferri J, **Wojcik T**, Nicot R. Twenty-four years of experience in management of complex mandibular fractures with low cost, custom-made mandibular external fixation: A 65-patient series. *J Stomatol Oral Maxillofac Surg*. 2019 Aug 30. pii: S2468-7855(19)30207-1. doi: 10.1016/j.jormas.2019.08.008.